Masatoshi Kudo

J-GLOBAL         Last updated: Oct 11, 2019 at 14:40
 
Avatar
Name
Masatoshi Kudo
Nickname
Masatoshi Kudo
E-mail
m-kudomed.kindai.ac.jp
Affiliation
Kindai University
Section
Faculty of Medicine
Research funding number
10298953

Research Areas

 
 

Published Papers

 
Takashima K, Matsui S, Komeda Y, Nagai T, Toshiharu S, Kashida H, Kudo M
Endoscopy      Aug 2019   [Refereed]
Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman W, Chintharlapalli S, Abada P, Sherman M, Zhu AX
Liver international : official journal of the International Association for the Study of the Liver      Aug 2019   [Refereed]
Yamao K, Takenaka M, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Kamata K, Minaga K, Hagiwara S, Sakurai T, Nishida N, Chiba Y, Watanabe T, Kudo M
Internal medicine (Tokyo, Japan)   58(14) 1993-2002   Jul 2019   [Refereed]
Kono M, Sakurai T, Okamoto K, Nagai T, Komeda Y, Kashida H, Minaga K, Kamata K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Enoki E, Inoue H, Matsumura I, Kudo M
Internal medicine (Tokyo, Japan)   58(14) 2029-2033   Jul 2019   [Refereed]
Takenaka M, Minaga K, Yoshikawa T, Okamoto A, Nakai A, Omoto S, Kudo M
Endoscopy      Jul 2019   [Refereed]
Takenaka M, Kamata K, Kudo M
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society      Jul 2019   [Refereed]
Takenaka M, Nakai A, Kudo M
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society      Jul 2019   [Refereed]
Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M
Cancers   11(7)    Jul 2019   [Refereed]
Kamata K, Watanabe T, Minaga K, Hara A, Yoshikawa T, Okamoto A, Yamao K, Takenaka M, Park AM, Kudo M
International immunology      Jul 2019   [Refereed]
Minami Y, Minami T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M
Hepatology research : the official journal of the Japan Society of Hepatology      Jul 2019   [Refereed]
Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M, Real-life Practice Experts for HCC (RELPEC) Study Group., HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).
Oncology   1-9   Jul 2019   [Refereed]
Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N
Hepatology research : the official journal of the Japan Society of Hepatology      Jun 2019   [Refereed]
Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW
British journal of cancer      Jun 2019   [Refereed]
Okamoto A, Watanabe T, Kamata K, Minaga K, Kudo M
Internal medicine (Tokyo, Japan)   58(11) 1533-1539   Jun 2019   [Refereed]
Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, Meier G, Pan J, Ishii M, Ikeda S
Journal of gastroenterology   54(6) 558-570   Jun 2019   [Refereed]
Hara A, Kamata K, Takenaka M, Chikugo T, Kudo M
Gastrointestinal endoscopy   89(6) 1257-1259   Jun 2019   [Refereed]
Takenaka M, Yoshikawa T, Okamoto A, Nakai A, Minaga K, Yamao K, Kudo M
Endoscopy   51(6) E132-E134   Jun 2019   [Refereed]
Minaga K, Watanabe T, Kamata K, Takenaka M, Yasukawa S, Kudo M
The American journal of gastroenterology   114(6) 1002-1003   Jun 2019   [Refereed]
Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Komeda Y, Kudo M
Journal of medical virology      Jun 2019   [Refereed]
Nishida N, Kudo M
Hepatology international   13(3) 248-252   Jan 2019   [Refereed]
Takenaka M, Okabe Y, Kudo M
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   51(5) 743   May 2019   [Refereed]
Minaga K, Watanabe T, Chung H, Kudo M
World journal of gastroenterology   25(19) 2308-2314   May 2019   [Refereed]
Kudo M
Liver cancer   8(3) 143-154   May 2019   [Refereed]
Hidaka H, Kurosaki M, Tanaka H, Kudo M, Abiru S, Igura T, Ishikawa T, Seike M, Katsube T, Ochiai T, Kimura K, Fukuhara T, Kano T, Nagata T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association   17(6) 1192-1200   May 2019   [Refereed]
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M, REACH-2 study investigators.
The Lancet. Oncology   20(2) 282-296   Feb 2019   [Refereed]
Risk factors for local recurrence and appropriate surveillance interval after endoscopic resection
Komeda Y, Watanabe T, Sakurai T, Kono M, Okamoto K, Nagai T, Takenaka M, Hagiwara S, Matsui S, Nishida N, Tsuji N, Kashida H, Kudo M
World J Gastroenterol   25 1502-1512   2019   [Refereed]
Targeted and immune therapy for hepatocellular carcinoma: predictions for 2019 and beyond
Masatoshi Kudo
World J Gastroenterol   25 789-807   2019   [Refereed]
Kudo M
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology   116(1) 8-17   2019   [Refereed]
Kato R, Hayashi H, Sano K, Handa K, Kumode T, Ueda H, Okuno T, Kawakami H, Matsumura I, Kudo M, Nakagawa K
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   13(12) e239-e241   Dec 2018   [Refereed]
Tak WY, Ryoo BY, Lim HY, Kim DY, Okusaka T, Ikeda M, Hidaka H, Yeon JE, Mizukoshi E, Morimoto M, Lee MA, Yasui K, Kawaguchi Y, Heo J, Morita S, Kim TY, Furuse J, Katayama K, Aramaki T, Hara R, Kimura T, Nakamura O, Kudo M
Investigational new drugs   36(6) 1072-1084   Dec 2018   [Refereed]
Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, Choi BI, Wilson SR, Kudo M, Barr RG
Ultrasound in medicine & biology   44(12) 2419-2440   Dec 2018   [Refereed]
Sofue K, Tsurusaki M, Mileto A, Hyodo T, Sasaki K, Nishii T, Chikugo T, Yada N, Kudo M, Sugimura K, Murakami T
Hepatology research : the official journal of the Japan Society of Hepatology   48(12) 1008-1019   Nov 2018   [Refereed]
Otsuka Y, Kamata K, Minaga K, Takenaka M, Watanabe T, Kudo M
Internal medicine (Tokyo, Japan)   57(21) 3075-3078   Nov 2018   [Refereed]
Takenaka M, Yamao K, Minaga K, Nakai A, Omoto S, Kamata K, Kudo M
Endoscopy      Nov 2018   [Refereed]
Watanabe T, Minaga K, Kamata K, Kudo M, Strober W
Trends in immunology   39(11) 874-889   Nov 2018   [Refereed]
Kudo M
Cancers   10(11)    Oct 2018   [Refereed]
Kudo M
Liver cancer   7(4) 305-311   Oct 2018   [Refereed]
Omoto S, Takenaka M, Kudo M
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society   31(1) e20-e21   Oct 2018   [Refereed]
Yoshikawa T, Watanabe T, Minaga K, Kamata K, Kudo M
Modern rheumatology   29(2) 1-18   Oct 2018   [Refereed]
Yamashita Y, Shimokawa T, Napoléon B, Fusaroli P, Gincul R, Kudo M, Kitano M
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society   31(2) 125-133   Oct 2018   [Refereed]
Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, Takenaka M, Ida H, Hagiwara S, Minami Y, Sakurai T, Watanabe T, Kudo M
Cancers   10(10)    Sep 2018   [Refereed]
Takenaka M, Minaga K, Kudo M
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society   30(5) 700-701   Sep 2018   [Refereed]
Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, García-Fiñana M, Kudo M, Kumada T, Roayaie S, Johnson PJ
Journal of hepatology      Sep 2018   [Refereed]
Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX
European journal of cancer (Oxford, England : 1990)   100 135-136   Sep 2018   [Refereed]
Takenaka M, Minaga K, Kudo M
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society   31(1) e1-e2   Aug 2018   [Refereed]
Takenaka M, Arisaka Y, Sakai A, Kobayashi T, Shiomi H, Masuda A, Kudo M
Endoscopy   50(8) E229-E230   Aug 2018   [Refereed]
Takenaka M, Yamao K, Kudo M
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society   30(6) 808-809   Aug 2018   [Refereed]
Yoshida A, Yamao K, Takenaka M, Nakai A, Omoto S, Kamata K, Minaga K, Miyata T, Imai H, Matsumoto I, Takeyama Y, Chikugo T, Kudo M
Internal medicine (Tokyo, Japan)   57(23) 3377-3380   Aug 2018   [Refereed]
Tateishi R, Seike M, Kudo M, Tamai H, Kawazoe S, Katsube T, Ochiai T, Fukuhara T, Kano T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M
Journal of gastroenterology   54(2) 171-181   Aug 2018   [Refereed]
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M, KEYNOTE-224 investigators.
The Lancet. Oncology   19(7) 940-952   Jul 2018   [Refereed]
Minaga K, Yamashita Y, Ogura T, Takenaka M, Shimokawa Y, Hisa T, Itonaga M, Kato H, Nishikiori H, Okuda A, Matsumoto H, Uenoyama Y, Watanabe T, Chiba Y, Higuchi K, Kudo M, Kitano M
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society   31(2) 180-187   Jul 2018   [Refereed]
Yen CJ, Muro K, Kim TW, Kudo M, Shih JY, Lee KW, Chao Y, Kim SW, Yamazaki K, Sohn J, Cheng R, Zhang Y, Binder P, Mi G, Orlando M, Chung HC
Journal of global oncology   (4) 1-12   Jul 2018   [Refereed]
Nishida N, Kudo M
Hepatology research : the official journal of the Japan Society of Hepatology   48(8) 622-634   May 2018   [Refereed]
Tamaki N, Koizumi Y, Hirooka M, Yada N, Takada H, Nakashima O, Kudo M, Hiasa Y, Izumi N
Hepatology research : the official journal of the Japan Society of Hepatology      Apr 2018   [Refereed]
Kamata K, Takenaka M, Minaga K, Nakai A, Omoto S, Miyata T, Yamao K, Imai H, Sakurai T, Watanabe T, Nishida N, Kudo M
Endoscopic ultrasound   7(5) 349-350   May 2018   [Refereed]
Tanaka H, Kamata K, Takenaka M, Kudo M
Internal medicine (Tokyo, Japan)      May 2018   [Refereed]
Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR
Cancer treatment reviews   68 16-24   May 2018   [Refereed]
Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX
British journal of cancer   119(1) 19-26   May 2018   [Refereed]
Minaga K, Watanabe T, Kamata K, Asano N, Kudo M
World journal of gastroenterology   24(16) 1725-1733   Apr 2018   [Refereed]
Matsui S, Kashida H, Kudo M
The American journal of gastroenterology   113(4) 462   Apr 2018   [Refereed]
Kamata K, Takenaka M, Minaga K, Omoto S, Miyata T, Yamao K, Imai H, Nakai A, Tanaka H, Chiba Y, Watanabe T, Sakurai T, Nishida N, Chikugo T, Matsumoto I, Takeyama Y, Kitano M, Kudo M
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society      Apr 2018   [Refereed]
Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y, SILIUS study group.
The lancet. Gastroenterology & hepatology      Apr 2018   [Refereed]
Kudo M
Liver cancer   7(1) 1-19   Mar 2018   [Refereed]
Minaga K, Takenaka M, Okamoto A, Omoto S, Miyata T, Imai H, Kudo M
Endoscopy   50(7) E153-154   Apr 2018   [Refereed]
Kamata K, Watanabe T, Minaga K, Strober W, Kudo M
Current protocols in immunology   120 15.31.1-15.31.8   Feb 2018   [Refereed]
Kudo M
Liver cancer   7(1) 20-27   Mar 2018   [Refereed]
Minaga K, Takenaka M, Kamata K, Yoshikawa T, Nakai A, Omoto S, Miyata T, Yamao K, Imai H, Sakamoto H, Kitano M, Kudo M
Cancers   10(2)    Feb 2018   [Refereed]
Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N, Liver Cancer Study Group of Japan.
Annals of surgery      Mar 2018   [Refereed]
Hagiwara S, Nishida N, Watanabe T, Ida H, Sakurai T, Ueshima K, Takita M, Komeda Y, Nishijima N, Osaki Y, Kudo M
Antiviral therapy   23(6) 513-521   Feb 2018   [Refereed]
Minami Y, Kudo M
Brain and nerve = Shinkei kenkyu no shinpo   70(2) 133-137   Feb 2018   [Refereed]
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL
Lancet (London, England)   391(10126) 1163-1173   Feb 2018   [Refereed]
Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N, Liver Cancer Study Group of Japan.
Liver international : official journal of the International Association for the Study of the Liver   38(3) 484-493   Mar 2018   [Refereed]
Dietrich CF, Averkiou M, Nielsen MB, Barr RG, Burns PN, Calliada F, Cantisani V, Choi B, Chammas MC, Clevert DA, Claudon M, Correas JM, Cui XW, Cosgrove D, D'Onofrio M, Dong Y, Eisenbrey J, Fontanilla T, Gilja OH, Ignee A, Jenssen C, Kono Y, Kudo M, Lassau N, Lyshchik A, Franca Meloni M, Moriyasu F, Nolsøe C, Piscaglia F, Radzina M, Saftoiu A, Sidhu PS, Sporea I, Schreiber-Dietrich D, Sirlin CB, Stanczak M, Weskott HP, Wilson SR, Willmann JK, Kim TK, Jang HJ, Vezeridis A, Westerway S
Ultrasound international open   4(1) E2-E15   Jan 2018   [Refereed]
Yamao K, Kitano M, Takenaka M, Minaga K, Sakurai T, Watanabe T, Kayahara T, Yoshikawa T, Yamashita Y, Asada M, Okabe Y, Hanada K, Chiba Y, Kudo M
Gastrointestinal endoscopy   88(1) 66-75.e2   Jan 2018   [Refereed]
Masatoshi Kudo
Hepatobil Surg Nutr      2018   [Refereed]
Yoshida A, Hagiwara S, Watanabe T, Nishida N, Ida H, Sakurai T, Komeda Y, Yamao K, Takenaka M, Enoki E, Kimura M, Miyake M, Kawada A, Kudo M
Internal medicine (Tokyo, Japan)   57(17) 2505-2509   2018   [Refereed]
Okamoto K, Watanabe T, Komeda Y, Okamoto A, Minaga K, Kamata K, Yamao K, Takenaka M, Hagiwara S, Sakurai T, Tanaka T, Sakamoto H, Fujimoto K, Nishida N, Kudo M
Frontiers in immunology   9 918   2018   [Refereed]
Utility of endoscopic ultrasound in hemorrhage from recurrent duodenal varices
Matsui S, Kashida H, Kudo M
Ann Gastroenterol   31 636   2018   [Refereed]
Management of hepatocellular carcinoma in Japan as a world-leading model
Masatoshi Kudo
Liver Cancer   7 134-147   2018   [Refereed]
Cabozantinib as a second-line agent in advanced hepatocellular carcinoma
Masatoshi Kudo
Liver Cancer   7 123-133   2018   [Refereed]
Nucleotide-binding oligomerization domain 1 and Helicobacter pylori infection: A review.
Minaga K, Watanabe T, Kamata K, Asano N, Kudo M
World J Gastroenterol      2018   [Refereed]
Kono M, Komeda Y, Sakurai T, Okamoto A, Minaga K, Kamata K, Hagiwara S, Inoue H, Enoki E, Matsumura I, Watanabe T, Kudo M
Journal of Crohn's & colitis      Dec 2017   [Refereed]
Minaga K, Kitano M, Itonaga M, Imai H, Miyata T, Yamao K, Tamura T, Nuta J, Warigaya K, Kudo M
Journal of medical ultrasonics (2001)   45(3) 391-397   Dec 2017   [Refereed]
Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Choo HY, Pressiani T, Burlone ME, Pirisi M, Giordano L, Abdulrahman A, Kudo M, Thimme R, Park JW, Pinato DJ
Liver cancer   6(4) 313-324   Nov 2017   [Refereed]
Otsuka Y, Kamata K, Takenaka M, Minaga K, Tanaka H, Kudo M
Endoscopy      Oct 2017   [Refereed]
Nishiyama H, Nagai T, Kudo M, Okazaki Y, Azuma Y, Watanabe T, Goto S, Ogata H, Sakurai T
Biochemical and biophysical research communications   495(1) 273-279   Oct 2017   [Refereed]
Minaga K, Takenaka M, Kamata K, Kudo M
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver      Oct 2017   [Refereed]
ALBI score as a novel tool in staging and treatment planning for hepatocellular carcinoma: advantage of ALBI grade for universal assessment of hepatic function.
Hiraoka A, Michitaka K, Kumada, Kudo M
Liver Cancer   6(4) 377-379   Oct 2017   [Refereed]
Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in japan: the need for a more detailed evaluation of hepatic function.
Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M, The Liver Cancer Study Group of Japan
Liver Cancer   6(4) 325-336   Oct 2017   [Refereed]
Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y
The lancet. Gastroenterology & hepatology   3(1) 37-46   Oct 2017   [Refereed]
Lenvatinib in advanced hepatocellular carcinoma.
Masatoshi Kudo
Liver Cancer   6(4) 253-263   Oct 2017   [Refereed]
Omoto S, Takenaka M, Kitano M, Miyata T, Kamata K, Minaga K, Arizumi T, Yamao K, Imai H, Sakamoto H, Harwani Y, Sakurai T, Watanabe T, Nishida N, Takeyama Y, Chiba Y, Kudo M
Oncology   93 Suppl 1 55-60   2017   [Refereed]
Okamoto K, Watanabe T, Komeda Y, Kono T, Takashima K, Okamoto A, Kono M, Yamada M, Arizumi T, Kamata K, Minaga K, Yamao K, Nagai T, Asakuma Y, Takenaka M, Sakurai T, Matsui S, Nishida N, Chikugo T, Kashida H, Kudo M
Oncology   93 Suppl 1 35-42   2017   [Refereed]
Yamao K, Takenaka M, Nakai A, Omoto S, Kamata K, Minaga K, Miyata T, Imai H, Sakurai T, Watanabe T, Nishida N, Matsumoto I, Takeyama Y, Chikugo T, Kudo M
Oncology   93 Suppl 1 81-86   2017   [Refereed]
Komeda Y, Handa H, Watanabe T, Nomura T, Kitahashi M, Sakurai T, Okamoto A, Minami T, Kono M, Arizumi T, Takenaka M, Hagiwara S, Matsui S, Nishida N, Kashida H, Kudo M
Oncology   93 Suppl 1 30-34   2017   [Refereed]
Takenaka M, Masuda A, Shiomi H, Yagi Y, Zen Y, Sakai A, Kobayashi T, Arisaka Y, Okabe Y, Kutsumi H, Toyama H, Fukumoto T, Ku Y, Kudo M, Azuma T
Oncology   93 Suppl 1 61-68   2017   [Refereed]
Okamoto K, Matsui S, Watanabe T, Asakuma Y, Komeda Y, Okamoto A, Rei I, Kono M, Yamada M, Nagai T, Arizumi T, Minaga K, Kamata K, Yamao K, Takenaka M, Sakurai T, Nishida N, Kashida H, Chikugo T, Kudo M
Oncology   93 Suppl 1 9-14   2017   [Refereed]

Misc

 
松井繁長, 樫田博史, 高島耕太, 岡元寿樹, 山田光成, 正木翔, 米田頼晃, 永井知行, 本庶元, 櫻井俊治, 辻直子, 工藤正俊
月刊消化器・肝臓内科   6(1) 7‐13   Jul 2019
上嶋一臣, 工藤正俊
Bio Clinica   34(7) 686‐690   Jul 2019
櫻井俊治, 樫田博史, 永井知行, 米田頼晃, 川上尚人, 中川和彦, 工藤正俊
消化器内視鏡   31(6) 928‐933   Jun 2019
南康範, 南知宏, 田北雅弘, 萩原智, 依田広, 上嶋一臣, 西田直生志, 工藤正俊
肝臓クリニカルアップデート   5(1) 39‐42   May 2019
竹中完, 中井敦史, 工藤正俊
消化器内視鏡   31(3) 348‐353   Mar 2019
上嶋一臣, 工藤正俊
臨床消化器内科   34(4) 448‐450   Mar 2019
渡邉智裕, 鎌田研, 吉川智恵, 三長孝輔, 工藤正俊
肝胆膵   78(2) 189‐195   Feb 2019
工藤正俊
医学のあゆみ   268(2) 146‐148   Jan 2019
工藤正俊, 工藤正俊, 池田公史, 上嶋一臣, 坂元亨宇, 椎名秀一朗, 建石良介, 長谷川潔, 古瀬純司, 宮山四朗, 村上卓道, 山下竜也, 國土典宏, 國土典宏
肝臓   60(2) 55‐62(J‐STAGE)   2019
鎌田研, 竹中完, 工藤正俊
週刊日本医事新報   (4940) 36‐40   Dec 2018
鎌田研, 竹中完, 石川嶺, 吉川智恵, 岡本彩那, 山崎友裕, 中井敦史, 大本俊介, 三長孝輔, 山雄健太郎, 櫻井俊治, 松井繁長, 渡邉智裕, 西田直生志, 樫田博史, 工藤正俊
胃と腸   53(13) 1795‐1799   Dec 2018
竹中完, 三長孝輔, 鎌田研, 山雄健太郎, 工藤正俊
消化器内視鏡   30(11) 1605‐1611   Nov 2018
竹中完, 吉川智恵, 石川嶺, 岡本彩那, 山崎友祐, 中井敦史, 大本俊介, 三長孝輔, 鎌田研, 山雄健太郎, 有坂好史, 工藤正俊
胆と膵   39 1013‐1020   Nov 2018
吉川智恵, 鎌田研, 竹中完, 大本俊介, 三長孝輔, 山雄健太郎, 今井元, 榎木英介, 木村雅友, 松本逸平, 竹山宜典, 工藤正俊
胆道   32(4) 775‐781   Oct 2018
渡邉智裕, 鎌田研, 三長孝輔, 工藤正俊
月刊リウマチ科   60(4) 347‐352   Oct 2018
竹中完, 筑後孝章, 工藤正俊
消化器内視鏡   30 54‐57,7   Oct 2018
田北雅弘, 南知宏, 千品寛和, 河野匡志, 萩原智, 南康範, 依田広, 上嶋一臣, 西田直生志, 工藤正俊
消化器内視鏡   30(8) 1086‐1089   Aug 2018
【レンビマで変わる肝細胞癌の診断と治療】 レンビマ徹底解剖 Phase 3 REFLECT試験
工藤 正俊
クリニシアン   65(7) 593-612   Jul 2018
急激に変貌する肝癌の薬物療法 肝細胞癌における免疫チェックポイント阻害薬とその他の治療法との組み合わせ治療
工藤 正俊
The Liver Cancer Journal   10(1) 49-55   Jul 2018
【どうする膵嚢胞】 IPMN IPMNの経過観察におけるEUSの今後
鎌田 研, 竹中 完, 中井 敦史, 大本 俊介, 宮田 剛, 三長 孝輔, 山雄 健太郎, 今井 元, 樫田 博史, 工藤 正俊
消化器内視鏡   30(5) 606-610   May 2018
膵管内乳頭粘液性腫瘍(IPMN)を疑う病変に対する初回精査として、腹部造影CTや磁気共鳴胆道膵管造影(MRCP)が用いられる。IPMNと診断されれば、次にhigh-risk stigmataやworrisome featureなどの悪性を示唆する所見の有無に関する診断が重要となる。IPMN/MCN国際診療ガイドライン2012年版(GL2012)では、worrisome featureを有する分枝型IPMNに対しては、超音波内視鏡(EUS)による精査が推奨されている。EUSにて悪性を疑う所見...
宮田 剛, 竹中 完, 工藤 正俊
臨床消化器内科   33(7) 950-957   May 2018
膵NETの最新の画像診断と治療 造影ハーモニックEUSによる膵神経内分泌腫瘍の悪性度評価
石川 嶺, 鎌田 研, 竹中 完, 田中 秀和, 中井 敦史, 大本 俊介, 宮田 剛, 三長 孝輔, 山雄 健太郎, 今井 元, 工藤 正俊
膵臓   33(3) 346-346   May 2018
術後膵液瘻(POPF)に対するEUS下ドレナージの有用性
中井 敦史, 竹中 完, 山雄 健太郎, 松本 逸平, 竹山 宜典, 工藤 正俊
膵臓   33(3) 399-399   May 2018
重症急性膵炎の予後不良予測因子および被包化壊死(WON)合併予測因子の検討
大本 俊介, 竹中 完, 松本 逸平, 竹山 宜典, 工藤 正俊
膵臓   33(3) 410-410   May 2018
造影ハーモニックEUSは膵癌の術前治療の効果判定に有用か?
田中 秀和, 鎌田 研, 竹中 完, 石川 嶺, 中井 敦史, 大本 俊介, 三長 孝輔, 宮田 剛, 山雄 健太郎, 今井 元, 工藤 正俊
膵臓   33(3) 505-505   May 2018
【知っておきたい神経感染症】 C型肝炎ウイルス関連クリオグロブリン血管炎
南 康範, 工藤 正俊
BRAIN and NERVE: 神経研究の進歩   70(2) 133-137   Feb 2018
C型肝炎ウイルス(HCV)関連クリオグロブリン血管炎では過剰な免疫応答によってクリオグロブリンが血中に増加し,これがさまざまな臓器の小血管を障害することで症状が生じる。主な症状は紫斑,関節痛,末梢性神経障害,レイノー現象がある。検査所見では血中クリオグロブリン陽性,赤沈亢進,C反応性蛋白の上昇,リウマチ因子陽性,補体価の低下が認められる。治療法として抗ウイルス療法,B細胞抑制療法,免疫抑制療法,血漿交換療法がある。(著者抄録)
幕谷 悠介, 松本 逸平, 大本 俊介, 筑後 孝章, 川口 晃平, 松本 正孝, 村瀬 貴昭, 亀井 敬子, 里井 俊平, 中居 卓也, 竹中 完, 工藤 正俊, 竹山 宜典
日本消化器外科学会雑誌   51(2) 114-121   Feb 2018
膵・胆管合流異常に合併した共通管内乳頭状腫瘍の1例を報告する.症例は75歳の男性で,6ヵ月間に2度の急性膵炎を発症し保存的加療で軽快した.急性膵炎の原因精査および加療目的で当院へ紹介となった.ERCPでは膵・胆管合流異常を認め,共通管内に7mmの結節様陰影欠損像を認めた.上部内視鏡検査では乳頭部からの粘液排出は認めず,超音波内視鏡検査では共通管内に乳頭状の腫瘍が描出された.造影CTでは膵頭部に拡張した共通管と内部に増強効果を持つ8mmの腫瘤を認めた.尾側の主膵管の拡張は認めなかった.膵・胆...
南 知宏, 南 康範, 千品 寛和, 有住 忠晃, 田北 雅弘, 矢田 典久, 萩原 智, 依田 広, 上嶋 一臣, 西田 直生志, 工藤 正俊
肝臓   59(2) 142-144   Feb 2018
肝細胞癌に対しUS-US overlay fusionを用いてラジオ波焼灼術(RFA)を行った53例68結節を対象に、US-US overlay fusionの有用性を検討した。早期の治療効果判定として、RFA後2〜3日以内に造影CTを撮像し、US-US overlay fusionでの評価と比較した。その結果、US-US overlay fusionガイドでFRA治療を行ったところ、全例が1セッションでtechnical successを達成した。穿刺回数は平均1.9回であり、造影CT/...
キーワード(No.3) パターン認識受容体
渡邉 智裕, 工藤 正俊
消化器病学サイエンス   1(3) 150-152   Dec 2017
微生物に対する免疫防御反応は、自然免疫反応と獲得免疫反応によって担われている。獲得免疫反応が効率よく誘導されるためには、自然免疫反応が不可欠である。自然免疫担当細胞に発現するパターン認識受容体(PRRs)は微生物由来抗原の認識を通して、自然免疫反応を誘導する。PRRsによる自然免疫反応は免疫防御だけでなく、慢性炎症にもかかわることが明らかになりつつある。(著者抄録)
KUDO Masatoshi
Nippon Shokakibyo Gakkai Zasshi   109(8) 1327-1334   2012
Miyata Hiroshi, Miyata Satoru, Kudo Masatoshi
Kanzo   53(12) 846-852   2012
In Japan the number of patients who are co-infected with hepatitis B and C virus is little. On the other hand there are many reports in the world that HBV reactivation often occur in the co-infected patients at the end of treatment or after IFN wi...
OGAWA Koichi, FUKUNAGA Kiyoshi, TAKEUCHI Tomoyo, KAWAGISHI Naoki, KUDO Masatoshi, OHKOUCHI Nobuhiro
Kanzo   52(11) 709-715   Nov 2011
Polycystic liver disease (PLD) is genetic disorder characterized by the progressive development of multiple liver cysts. Because of rarity of PLD, therapeutic consensus is controversial. The aim of this study was to investigate a situation of PLD ...
Maki Tomonori, Shiina Tsuyoshi, Yamakawa Makoto, Mitake Tsuyoshi, Kudo Masatoshi, Fujimoto Kenji
Proceedings of Symposium on Ultrasonic Electronics   (32) 141-142   Nov 2011
Kudo Masatoshi
Journal of Japan Surgical Society   112(2) 122-129   Mar 2011
KITANO Masayuki, KOMAKI Takamitsu, SAKAMOTO Hiroki, IMAI Hajime, KAMATA Ken, KUDO Masatoshi, YASUDA Takeo, TAKEYAMA Yoshifumi
26(1) 23-28   Feb 2011
KITANO Masayuki, KUDO Masatoshi
GASTROENTEROLOGICAL ENDOSCOPY   53(1) 76-86   Jan 2011
The development of the second generation ultrasound contrast Sonazoid which produces a second harmonic component with low acoustic power has enabled vascular assessment in the field of EUS. With the use of the echoendoscope provided by OLYMPUS-ALO...
UESHIMA Kazuomi, KUDO Masatoshi
Kanzo   51(11) 681-683   Nov 2010
Fifty patients with advanced hepatocellular carcinoma (HCC) were treated with sorafenib. In 25 of the patients, serum levels of protein induced by vitamin K absence or antagonist II (PIVKA-II) were evaluated at two time points (pretreatment and wi...
FUJIMOTO Kenji, KATO Michio, TONOMURA Akiko, YADA Norihisa, TATSUMI Chie, OSHITA Masahide, WADA Shigeo, UESHIMA Kazuomi, ISHIDA Tetsushi, FURUTA Tomoko, YAMASAKI Masaru, TSUJIMOTO Masahiko, MOTOKI Mitsuru, MITAKE Tsuyoshi, KIM Shigehiro, YAMAMOTO Keiji, SHIINA Tsuyoshi, KUDO Masatoshi, HAYASHI Norio
Kanzo   51(9) 539-541   Sep 2010
To evaluate the effectiveness of Real-time Tissue Elastography (RTE) in staging of liver fibrosis non-invasively, we performed RTE on 310 patients with chronic hepatitis C (and/or liver cirrhosis) and 15 healthy volunteers. Nine image features wer...
MIYATA Hiroshi, MIYATA Satoru, KUDO Masatoshi
Kanzo   51(7) 371-378   Jul 2010
Elevated serum ALT levels sometimes have been observed in CHC patients receiving pegylated interferon (PEG-IFN) therapy. However the reason for this elevation hasn't been clarified and in these cases we often hasitate to continue PEG-IFN therapy. ...
MIZOKAMI Masashi, TANAKA Eiji, CHAYAMA Kazuaki, TANAKA Yasuhito, KUROSAKI Masayuki, IZUMI Namiki, ARASE Yasuji, KUMADA Hiromitsu, IMAZEKI Fumio, YOKOSUKA Osamu, KUDO Masatoshi
Kanzo   51(5) 243-260   May 2010
OKANOUE Takeshi, SAIBARA Toshiji, ONO Masafumi, SUMIDA Yoshio, HASHIMOTO Etsuko, TAMURA Shinji, YAMADA Gotaro, KAWADA Sumio, KUDO Masatoshi
Kanzo   50(12) 741-747   Dec 2009
KUDO Masatoshi
Nippon Shokakibyo Gakkai Zasshi   106(12) 1712-1726   Dec 2009
NISHIGUCHI Shuhei, IZUMI Namiki, HINO Keisuke, SUZUKI Fumitaka, KUMADA Hiromitsu, ITO Yoshito, ASAHINA Yasuhiro, TAMORI Akihiro, HIRAMATSU Naoki, HAYASHI Norio, KUDO Masatoshi
Kanzo   50(11) 665-677   Nov 2009
ARII Shigeki, MISHIRO Shunji, MATSUI Osamu, IZUMI Namiki, KUDO Masatoshi, KOKUDO Norihiro
Kanzo   50(8) 407-426   Aug 2009
KITANO Masayuki, SAKAMOTO Hiroki, KUDO Masatoshi
35(6) 663-670   Nov 2008
Kudo Masatoshi
Nihon Naika Gakkai Zasshi   97(7) 1681-1689   Jul 2008
KIM Soo Ryang, IMOTO Susumu, FUKI Shuichi, KIM Ke Ih, TANIGUCHI Miyuki, NAGANO Motoko, HOTTA Hak, SHOUJI Ikuo, KANBARA Yoshihiro, MAEKAWA Yoko, KUDO Masatoshi, HAYASHI Yoshitake
Kanzo   49(4) 145-152   Apr 2008
The patients (n=75) in this study had chronic hepatitis C with high viral loads of serum HCV-RNA genotype 1b. All the patients received a regimen of pegylated interferon α-2b plus ribavirin (PEG IFN α-2b/RBV) for 48 weeks. Comparative analysis was...
KITANO Masayuki, SAKAMOTO Hiroki, KUDO Masatoshi
35    Apr 2008
FUJIMOTO Kenji, TATSUMI Chie, UESHIMA Kazuomi, MAEKAWA Kiyoshi, KATO Michio, KUDO Masatoshi, TONOMURA Akiko, YAMAKAWA Makoto, SHIINA Tsuyoshi
35    Apr 2008
MAEKAWA Kiyoshi, HATANAKA Kinuyo, YOKOGAWA Mika, MAENO Tomoko, ICHIJIMA Mayumi, INOUE Tatuo, MINAMI Yasunori, TEI Hiroshi, UESHIMA Kazuomi, KUDO Masatoshi
35    Apr 2008
HATANAKA Kinuyo, MINAMI Yasunori, KITAI Satoshi, TATSUMI Chie, TAKAHASHI Syunsuke, INOUE Tatsuo, HAGIWARA Satoru, CHUNG Hobyung, UESHIMA Kazuomi, KUDO Masatoshi
35    Apr 2008
KOKUDO Norihiro, MAKUUCHI Masatoshi, NAKAYAMA Takeo, ARII Shigeki, OMATA Masao, KUDO Masatoshi, KOJIRO Masamichi, SAKAMOTO Michiie, TAKAYASU Ken-ichi, HAYASHI Norio, MONDEN Morito
Kanzo   48(11) 562-570   Nov 2007
"Clinical practice guidelines for hepatocellular carcinoma (HCC)," the first evidence-based guidelines for the treatment of HCC in Japan (the J-HCC Guidelines) have been compiled and English translation has just been completed (http://www.jsh.or.j...
SAKAMOTO Hiroki, KITANO Masayuki, SUETOMI Yoichiro, SHIOMI Mikio, KOMAKI Takahiro, NODA Kazu, TATUMI Chie, UESHIMA Kazuomi, KUDO Masatoshi
Gastroenterol Endosc   49(8) 1844-1847   Aug 2007
KUDO Masatoshi, HATANAKA Kinuyo, CHUNG Hobyung, MINAMI Yasunori, MAEKAWA Kiyoshi
Kanzo   48(6) 299-301   Jun 2007
We have innovated new imaging technique, Defect Re-perfusion Imaging, in the Sonazoid-enhanced contrast ultrasonography (US) for hepatocellular carcinoma (HCC), which is not clearly demonstrated on B mode US. Firstly, perfusion defect can be detec...
MINAMI Yasunori, KUDOU Masatoshi
34    Apr 2007
KITANO Masayuki, SAKAMOTO Hiroki, MATSUI Uwe, ITO Yasuhiro, MAEKAWA Kiyoshi, VON SCHRENCK Tammo, KUDO Masatoshi
34    Apr 2007
FUJIMOTO Kenji, TATSUMI Chie, UESHIMA Kazuomi, MAEKAWA Kiyoshi, TONOMURA Akiko, MITAKE Tsuyoshi, YAMAKAWA Makoto, KATO Michio, KUDOU Msatoshi, SHIINA Tsuyoshi
34    Apr 2007
MAEKAWA Kiyoshi, INOUE Tatuo, MINAMI Yasunori, TEI Hiroshi, UESHIMA Kazuomi, HUKUNAGA Toyokazu, KUDOU Masatoshi
34    Apr 2007
KUWAGUCHI Ai, KUDO Masatoshi, KAWASAKI Toshihiko, MAENO Tomoko, ICHIZIMA Mayumi, MAEKAWA Kiyoshi, INOUE Tatuo, ITOU Tatuki
32(6) 539-545   Nov 2005
KUWAGUCHI Ai, KUDO Masatoshi, KAWASAKI Toshihiko, MAENO Tomoko, ICHIZIMA Mayumi, MAEKAWA Kiyoshi, INOUE Tatuo, ITOU Tatuki
32(6) 539-545   Nov 2005
FUKUTA Nobuhiro, KITANO Masayuki, MAEKAWA Kiyoshi, KUDO Masatoshi
32    Apr 2005
KITANO Masayuki, SAKAMOTO Hiroki, MAEKAWA Kiyoshi, MINAMI Yasunori, NAKAOKA Ryousuke, NAKATANI Tatsuya, KUDO Masatoshi
32    Apr 2005
SAKAMOTO Hiroki, KITANO Masayuki, MAEKAWA Kiyoshi, KUDO Masatoshi
32    Apr 2005
KITANO Masayuki, SAKAMOTO Hiroki, MAEKAWA Kiyoshi, KUDO Masatoshi
32    Apr 2005
MAEKAWA Kiyoshi, INOUE Tatuo, MINAMI Yasunori, TEI Hiroshi, UESHIMA Kazuomi, HUKUNAGA Toyokazu, KUDOU Masatoshi
32    Apr 2005
FUKUTA Nobuhiro, KITANO Masayuki, MAEKAWA Kiyoshi, KUDO Masatoshi
32    Apr 2005
KITANO Masayuki, SAKAMOTO Hiroki, MAEKAWA Kiyoshi, MINAMI Yasunori, NAKAOKA Ryousuke, NAKATANI Tatsuya, KUDO Masatoshi
32    Apr 2005
SAKAMOTO Hiroki, KITANO Masayuki, MAEKAWA Kiyoshi, KUDO Masatoshi
32    Apr 2005
KITANO Masayuki, SAKAMOTO Hiroki, MAEKAWA Kiyoshi, KUDO Masatoshi
32    Apr 2005
MAEKAWA Kiyoshi, INOUE Tatuo, MINAMI Yasunori, TEI Hiroshi, UESHIMA Kazuomi, HUKUNAGA Toyokazu, KUDOU Masatoshi
32    Apr 2005
KUDO Masatoshi
Kanzo   46(2) 53-63   Feb 2005
In this article, the concept and clinical impact of the staging systems for hepatocellular carcinoma (HCC) were reviewed. Among the several scoring systems so far available, such as Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian...
FUKI Syuichi, KIM Soo Ryang, NINOMIYA Tosiaki, MAEKAWA Yoko, KIM Ke Ih, IMOTO Susumu, KUDO Masatoshi
Kanzo   45(12) 666-670   Dec 2004
MIZUNO Shigeto, HONJO Hajime, KUDO Masatoshi
18(1) 23-28   Mar 2004
KASUGAI Hiroshi, OSAKI Yukio, OKA Hiroko, KUDO Masatoshi, SEKI Toshihito, Osaka liver cancer study group
Kanzo   44(12) 632-640   Dec 2003
This study was undertaken to obtain the information about the present condition of radiofrequency ablation (RFA) for hepatocellular carcinoma.The data of 2614 patients, who underwent RFA between January 1999 and May 2002, were gathered and analyze...
OKA Hiroko, OSAKI Yukio, KASUGAI Hiroshi, KUDO Masatoshi, SEKI Toshihito, Osaka liver cancer study group
Kanzo   44(11) 546-551   Nov 2003
The present study deals with the natural history of 195 patients with hepatocellular carcinoma who were seen from 1990 to 2000. One-year survival of overall patients was 31%, 3-year was 10%, and 5-year was 3%. The 1-, 3-, 5-yr survival for 13 pati...
KUDO M
Kanzo   44(6) 250-258   Jun 2003
KUDO Masatoshi
29(6) J535-J536   Nov 2002
Kudo Masatoshi
Journal of Microwave Surgery   20 17-25   2002
Areas of residual tumors after RFA or PEI therapy are not distinguishable from necrotic tissues on US. The sonographic findings of gray-scale, color Doppler and power Doppler scanning after RFA or PEI therapy do not correlate well with the overall...
KUDO Masatoshi
Nippon Shokakibyo Gakkai Zasshi   98(7) 795-808   Jul 2001
TEI H., KUDO M., MAEKAWA K.
28(3)    Apr 2001
MINAMI Y., WEN YL., SUETOMI Y, TEI H., ONDA H., KAWASAKI T., KUDO M., KUWAGUCHI A., MAEKAWA K.
28(3)    Apr 2001
KAWASAKI T., WEN Y., MINAMI Y., SUETOMI Y., TEI H., ONDA K., KUDO M., EGUCHI M., MAEKAWA K., DING H.
28(3)    Apr 2001
MAEKAWA K., OTANI M., WEN Y., DING H., SUETOMI Y., TEI H., MINAMI Y., ONDA H., KAWASAKI T., KUDO M.
28(3)    Apr 2001

Books etc

 
IgG4-related disease and innate immunity. In “IgG4-Related Disease”, Curr Top Microbiol Immunol, Okazaki K, ed
Watanabe T, Yamashita K, Kudo M (Part:Joint Work, Vol. 401, pp115-128)
Springer   2017   
Liver Cancer, Okuda K and Tabor E, eds, Ultrasound Diagnosis
Churchill Livingstone, London   1997   
"Diagnosis and Treatment of Hepatocellular Carcinoma", Livraghi T, Makuuchi M, Buscarini, eds, Scintigraphy
Greenwich Medical Media Limited, London, UK   1997   
"Hepatology in the 21st Century: Diagnosis and Therapy." Tanikawa K, Kojiro M, Gollan J, eds, Advances in diagnostic imaging of hepatocellular carcinoma
IASL, APASL, and JSH JOINT POST GRADUATE TEXTBOOK, IASL Publ, Fukuoka   2000   

Conference Activities & Talks

 
Checkmate 040: efficacy, hepatic safety, and biomarkers of Nivolumab + Ipilimumab combination therapy in patients with advanced hepatocellular carcinoma
Sangro B, Hsu C, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, He AR, El-Rayes B, Acosta-Rivera M, Lim HY, Neely J, Zhao H, Anderson J, Yau T
American Association for the Study of Liver Diseases (AASLD 2019)   11 Nov 2019   
Safety and efficacy of Lenvatinib by starting dose based on bodyweight in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT
Okusaka T, Ikeda K, Kudo M, Finn RS, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H
31th Annual Conference, Canadian Association of Nurses in Oncology (CANO 2019)   21 Oct 2019   
Association between overall survival and adverse events with Lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT)
Sung M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Kudo M, Tateishi R, Ikeda M, Breder V, Rau KM, Ma YT, Alsina A, Ryoo BY, Ren Z, Mody K, Dutcus C, Tamai T, Saito K, Piscaflia F
31th Annual Conference, Canadian Association of Nurses in Oncology (CANO 2019)   21 Oct 2019   
Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein: an exposure-response analysis
Llovet JM, Kudo M, Kang YK, Yen CJ, Finn RS, Gale PR, Assenat E, Motomura K, Okusaka T, Berg T, Hsu CH, Ikeda M, Hsu Y, Liang K, Widau R, Schelman W, O’Braian L, Gao L, Zhu AX
European Society for Medical Oncology (ESMO 2019)   29 Sep 2019   
Health-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240
Merle P, Kulkarni AS, Ryoo BY, Cheng AL, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist J, Chen E, Siegel AB, Zhu AX, Finn RS
European Society for Medical Oncology (ESMO 2019)   27 Sep 2019   
Pembrolizumab vs placebo as adjuvant therapy in patients with hepatocellular carcinoma (HCC) and complete radiological response following surgical resection or local ablation: Phase 3 KEYNOTE-937 trial
Zhu AX, Cheng AL, Vogel A, Yau T, Zhou J, Chen E, Malhotra U, Siegel AB, Kudo M
13th Annual Conference International Liver Cancer Association (ILCA)   Sep 2019   
First-line combination therapy with lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma: Phase 3 Leap-002 study
Llovet JM, Kudo M, Cheng AL, Finn RS, Galle PR, Kaneko S, Meyer T, Qin S, Dutcus CE, Chen E, Dubrovsky L, Zhu AX
13th Annual Conference International Liver Cancer Association (ILCA)   Sep 2019   
Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)
Meyer T, Finn R, Kudo M, Kang YK, Yen CJ, Galle P, Llovet J, Assenat E, Brandi G, Motomura K, Okusaka T, Hubner R, Karwal M, Baron A, Ikeda M, Liang K, Wang C, Widau R, Schelman W, Zhu A
ESMO 21th World Congress on Gastrointestinal Cancer 2019 (ESMO-WCGC 2019)   3 Jul 2019   
Invited Lecture “Recent trends of treatment for intermediate stage HCC: Japanese experience” [Invited]
Masatoshi Kudo
The Liver Week 2019   21 Jun 2019   
Efficacy, safety, and cancer-related symptoms in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies
Borbath I, Kudo M, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Peck-Radosavljevic M, Girvan A, Gable J, Bowman L, Abada P, Hsu Y, Zhu AX, Lee SY
Osterreichische Gesellschaft fur Gastroenterologie und Hepatologie (OGGH 2019)   Jun 2019   
State-of-the-Art Lecture “IO in liver cancer therapy now and future.” [Invited]
Masatoshi Kudo
2019 Joint International Conference of Taiwan Liver Cancer Association and Taiwan Academy of Tumor Ablation: Precision medicine in HCC: research and treatment   26 May 2019   
Keynote Lecture “When is the best time for TKI (LEN) be used in BCLC B & C HCC patients." [Invited]
Masatoshi Kudo
Expert Round Table Meeting for Unresectable Hepatocellular Carcinoma   26 May 2019   
Invited Lecture “Evolving roles of targeted therapy in HCC” [Invited]
Masatoshi Kudo
the 3rd Symposium of the Singapore Liver Cancer Consortium (SLCC)   3 May 2019   
Lenvatinib (lenva) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study
Llovet J, Kudo M, Cheng AL, Finn R, Galle P, Kaneko S, Meyer T, Qin S, Dutcus C, Chen E, Dubrovsky L, Zhu A
American Society of Clinical Oncology Annual Meeting (ASCO 2019)   May 2019   
A phase 1b trial of Lenvatinib (LEN) plus Pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results.
Ikeda M, Sung MW, Kudo M, Kobayashi M, Baron AD, Finn RS, Kaneko S, Zhu AX, Kubota T, Kraljevic S, Ikezawa H, Dubrovsky L, Siegel AB, Kumada H, Okusaka T
American Association for Cancer Research Annual Meeting (AACR 2019)   1 Apr 2019   
Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis
Peck-Radosavljevic M, Lee HC, Kudo M, Nakajima K, Bayh I, Cheng AL, Raoul JL
The International Iiver Congress (EASL 2019)   Apr 2019   
Efficacy, safety, and patient-reported outcomes in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies
Borbath I, Kudo M, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Peck-Radosavljevic M, Girvan A, Gable J, Bowman L, Abada P, Hsu Y, Zhu AX
Belgian Week of Gastroenterology   22 Feb 2019   
Practice patterns, response rates, and deterioration of liver function after transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC): Final analysis of OPTIMIS in China
Shan H, Lee HC, Raoul JL, Peck-Radosavljevic M, Kudo M, Nakajima K, Bayh I, Yang Y, Wang W, Cheng AL
The 28th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL 2019)   Feb 2019   
Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): an analysis of AFP kinetics in the phase 3 REACH-2 study.
Finn RS, Kudo M, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Lim HY, Pracht M, Rau KM, Merle P, Motomura K, Ohno I, Daniele B, Shin D, Gerken G, Abada P, Hsu Y, Zhu AX
American Society of Clinical Oncology, Gastrointestinal Cancers Symposium (ASCO-GI 2019)   18 Jan 2019   
Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study
Ogasawara S, Ueshima K, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura T, Kuroda H, Ohki T, Nagashima K, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato N, Kudo M, Omata M
American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)   18 Jan 2019   
CheckMate-040: Nivolumab (NIVO) in patients (Pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status
Kudo M, Matilla A, Santoro A, Melero I, Gracian A, Acosta MR, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, dela Cruz C, Baccan C, Sangro B
American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)   18 Jan 2019   
Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase 3 study of lenvatinib (REFLECT)
Kudo M, Finn RS, Qin S, Han KH Ikeda K, Cheng AL, Piscaglia F, Ueshima K, Aikata H, Vogel A, Lopez C, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Dutcus C, Tamai T, Saito K, Lencioni R
American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)   18 Jan 2019   
Subsequent anticancer medication following first-line lenvatinib: a posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma
Alsina A, Kudo M, Vogel A, Cheng AL, Tak WY, Ryoo BY, Evans TJ, Lopez CL, Daniele B, Misir S, Ren M, Izumi N, Qin S, Finn RS
American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)   18 Jan 2019   
Safety and efficacy of lenvatinib by starting dose based on bodyweight in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT
Okusaka T, Ikeda K, Kudo M, Finn RS, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrxicz L, Yoon JH, Ren Z, Stepan D, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H
American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)   18 Jan 2019   
Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT)
Sung M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Kudo M, Tateishi R, Ikeda M, Breder V, Rau KM, Ma YT, Alsina A, Ryoo BY, Ren Z, Mody K, Dutcus C, Tamai T, Saito K, Piscaglia F
American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)   18 Jan 2019   
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studi
Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX
American Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)   17 Jan 2019   
Invited Lecture “HCC and cholangiocarcinoma” [Invited]
Masatoshi Kudo
Hot Topics at AASLD 2018   16 Dec 2018   
Invited Lecture “Newer diagnostic algorithm for a solid tumor <3 cm in a cirrhotic” [Invited]
Masatoshi Kudo
Hot Topics at AASLD 2018   16 Dec 2018   
Practice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions
Heo J, Cheng AL, Raoul JL, Peck-Radosavljevic M, Kudo M, Nakajima K, Bayh I, Lin SM, Lee HC
European Society for Medical Oncology Congress (ESMO-Asia 2018)   25 Nov 2018   
Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies
Kang YK, Kudo M, Lim HY, Hsu CH, Vogel A, Brandi G, Cheng R, Carton I, Abada P, Hsu Y, Zhu A, Yen CJ
European Society for Medical Oncology Congress (ESMO-Asia 2018)   25 Nov 2018   
M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype
Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M
European Society for Medical Oncology Congress (ESMO-Asia 2018)   24 Nov 2018   
Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
Chan SL, Finn RS, Zhu AX, Knox J, Cheng AL, Siegel AB, Bautista O, Kudo M
European Society for Medical Oncology (ESMO)-ASIA 2017   18 Nov 2018   
Clinical efficacy and safety of EUS-guided gallbladder drainage replacement of percutaneous drainage: A multicenter retrospective study in Japan
Minaga K, Yamashita Y, Ogura T, Takenaka M, Shimokawa Y, Hisa T, Itonaga M, Kato H, Nishikiori H, Okuda A, Matsumoto H, Uenoyama Y, Watanabe T, Chiba Y, Higuchi K, Kudo M, Kitano M
Asian Pacific Digestive Week (APDW 2018)   17 Nov 2018   
Nivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma (aHCC) in the CheckMate-040 study
Kudo M, Matilla A, Santoro A, Melero I, Gracian AC, Acosta MR, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, dela Cruz C, Baccan C, Sangro B
American Association for the study of liver diseases (AASLD 2018)   12 Nov 2018   
New diagnostic method for hepatic steatosis using attenuation measurement by ultrasound B mode: comparison with controlled attenuation parameter
Koizumi Y, Hirooka M, Yada N, Tamaki N, Izumi N, Kudo M, Hiasa Y
American Association for the study of liver diseases (AASLD 2018)   12 Nov 2018   
Stem cell feature and immune-suppressive microenvironment in human hepatocellular carcinoma
Nishida N, Kudo M
American Association for the study of liver diseases (AASLD 2018)   12 Nov 2018   
Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis
Peck-Radosavljevic, Kudo M, Raoul JL, Lee HC, Decaens T, Heo J, Lin SM, Shan H, Yang Y, Bayh I, Nakajima K, Cheng AL
American Association for the study of liver diseases (AASLD 2018)   12 Nov 2018   
Ramucirumab as second-line treatment in patients with hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following sorafenib: pooled results from two global phase 3 studies (REACH-2 and REACH)
Llovet JM, Kudo M, Finn R, Galle PR, Blanc JF, Okusaka T, Chau I, Abada PB, Hsu Y, Zhu AX
American Association for the study of liver diseases (AASLD 2018)   12 Nov 2018   
Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: multicenter analysis
Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M
American Association for the study of liver diseases (AASLD 2018)   10 Nov 2018   
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib (REACH-2): efficacy, safety, and patient-reported outcome results
Zhu A, Finn R, Galle P, Llovet J, Nipp R, Cella D, Girvan A, Gable J, Bowman L, Abada P, Hsu Y, Kudo M
Gastrointestinal Oncology Conference 2018 (ISGIO)   1 Nov 2018   
Special Remarks, International Session (Symposium) 2 “Hepatitis towards the control of HCC-the remaining issues and future directions in Japan and the world” [Invited]
Masatoshi Kudo
Japan Digestive Disease Week 2018 (JDDW 2018)(the 60th Annual Meeting of the Japanese Society of Gastroenterology, the 96th Congress of the Japan Gastroenterological Endoscopy Society, the 22nd General Meeting of the Japan Society of Hepatology)   1 Nov 2018   
Independent imaging review analysis of REFLECT trial of lenvatinib in HCC
Aikata H, Kudo M, Ikeda K
Japan Digestive Disease Week (JDDW 2018)(The 60th Annual Meeting of the Japanese Society of Gastroenterolgy, the 22nd General Meeting of the Japan Society of Hepatology, the 96th Congress of the Japan Gastroenterological Endoscopy Society)   1 Nov 2018   
Practice patterns in the treatment of unresectablehepatocellular carcinoma with sorafenibin Latin America according to Child–Pugh score: Subgroup analysis of the GIDEON study
Ladron de Guevara L, Dagher L, Miguel Viana Arruda V, Nakajima K, Kudo M
Mexican Society of Oncology 36th National Congress 2018 (SMEO 2018)   Nov 2018   
Global phase 3 study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress
Qin S, Finn R, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla T, Tomasello G, Boisserie F, Hou J, Li C, Song J, Zhu A
European Society for Medical Oncology (ESMO 2018)   21 Oct 2018   
Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada
Raoul JL, Decaens T, Burak K, Koskinas J, Villadsen GE, Heurgue-Berlot A, Bayh I, Cheng AL, Kudo M, Lee HC, Nakajima K, Peck-Radosavljevic M
European Society for Medical Oncology (ESMO 2018)   21 Oct 2018   
A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
Cheng AL, Yen CJ, Okusaka T, Ikeda M, Hsu CH, Wu SY, Morizane C, Hashimoto Y, Ueshima K, Ohtomo T, Tanaka T, Kudo M
European Society for Medical Oncology (ESMO 2018)   21 Oct 2018   
Invited Lecture “HCC Meet the Expert” [Invited]
Masatoshi Kudo
European Society for Medical Oncology (ESMO 2018)   21 Oct 2018   
Final analysis of serum biomarkers in patients (pts) from the phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
Finn RS, Kudo M, Cheng AL, Wyrwicz L, Ngan R, Blanc JF, Baron A, Vogel A, Ikeda M, Piscaglia F, Han KH, Qin S, Minoshima Y, Kanekiyo M, Ren M, Dairiki R, Tamai T, Dutcus C, Funahashi Y, Evans TRJ
European Society for Medical Oncology (ESMO 2018)   20 Oct 2018   
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: patient reported outcome results across two phase 3 studies (REACH-2 and REACH)
Zhu AX, Finn R, Galle P, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Girvan A, Gable J, Bowman L, Hsu Y, Abada P, Kudo M
European Society for Medical Oncology (ESMO 2018)   19 Oct 2018   
Invited Lecture “The Role of CEUS in the Detection and Diagnosis of FLL” [Invited]
Masatoshi Kudo
The 2018 Convention of Taiwan Society of Ultrasound in Medicine (TSUM)   14 Oct 2018   
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial
Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M
European Society for Medical Oncology (ESMO 2018)   Oct 2018   
Stress response protein RBM3 promotes the development of colitis-associated cancer [Invited]
Sakurai T, Kudo M
The 77th Annual Meeting of the Japanese Cancer Association   28 Sep 2018   
Systemic therapy for hepatocellular carcinoma: current status and future perspective. Symposia on Specific Tumors “Current status and the future of hepatobiliary and pancreatic cancer research and treatment” [Invited]
Masatoshi Kudo
The 77th Annual Meeting of the Japanese Cancer Association   27 Sep 2018   
Chair: Symposia on Specific Tumors “Current status and the future of hepatobiliary and pancreatic cancer research and treatment” [Invited]
Masatoshi Kudo
The 77th Annual Meeting of the Japanese Cancer Association   27 Sep 2018   
Hand-foot syndrome as a predictor of survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study
Ogawa C, Shibatoge M, Takaguchi K, Tani J, Morishita A, Yoneyama H, Masaki T, Moriya A, Ando M, Deguchi A, Kudo M
12th Annual Conference International Liver Cancer Association (ILCA)   15 Sep 2018   
Urine protein: creatinine ratio (UPCR) vs 24-h urine protein for the management of proteinuria: results from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) in hepatocellular carcinoma (HCC)
Evans TR, Kudo M, Finn RS, Han KH, Cheng AL, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW
12th Annual Conference International Liver Cancer Association (ILCA)   15 Sep 2018   
Acute and chronic deterioration in liver function after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): the final analysis of OPTIMIS
Cheng AL, Raoul JL, Lee HC, Bayh I, Nakajima K, Peck-Radosavljevic M, Kudo M
12th Annual Conference International Liver Cancer Association (ILCA)   15 Sep 2018   
Newly proposed tools for assessment of hepatic function for hepatocellular carcinoma staging and treatment planning-usefulness of modified ALBI grade
Izumoto H, Hiraoka A, Kumada T, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Ninomiya T, Michitaka K, Kudo M
12th Annual Conference International Liver Cancer Association (ILCA)   15 Sep 2018   
Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (PTS) with unresectable hepatocellular carcinoma (UHCC)
Lencioni R, Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Piscaglia F, Han G, Ikeda M, Simon K, Komov D, OuYang X, Evans TR, Sung M, Binder T, Damon A, Kraljevic S, Ren M, Ryoo BY
12th Annual Conference International Liver Cancer Association (ILCA)   15 Sep 2018   
Overall survival (OS) update: 2-year follow-up from the phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) progressing on sorafenib
Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Qin S, Song T, Bronowicki JP, Ollivier-Houmand I, Kudo M, LeBerre MA, Baumhauer A, Meinhardt G, Han G and on behalf of the RESORCE Investigators
12th Annual Conference International Liver Cancer Association (ILCA)   15 Sep 2018   
A cost-effectiveness analysis of Lenvatinib compared with sorafenib in unresectable hepatocellular carcinoma allowing for AFP adjustment in overall survival in Japan from the reflect phase 3 clinical trial
Kudo M, Izumi N, Kaneko S, Kobayashi M, Azuma MK, Copher R, Meier G, Ishii M, Ikeda S
12th Annual Conference International Liver Cancer Association (ILCA)   15 Sep 2018   
Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Ueshima K, Kudo M, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Arai Y, and TACTICS study group
12th Annual Conference International Liver Cancer Association (ILCA)   15 Sep 2018   
Outcomes of patients (PTS) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global optimis final analysis
Peck-Radosavljevic M, Kudo M, Raoul JL, Lee HC, Decaens T, Heo J, Lin SM, Shan H, Yang Y, Bayh I, Nakajima K, Cheng AL
12th Annual Conference International Liver Cancer Association (ILCA)   15 Sep 2018   
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2): a phase 3, randomized, double-blind, placebo-controlled trial
Galle PR, Kudo M, Kang YK, Yen CJ, Finn R, Llovet JM, Assenat E, Brandi G, Lim HY, Pracht M, Rau KM, Merle P, Motomura K, Ohno I, Daniele B, Shin DB, Gerken G, Abada P, Hsu Y, Zhu AX
12th Annual Conference International Liver Cancer Association (ILCA)   15 Sep 2018   
Chair: General Session 3 “Epidemiology, Diagnosis, Staging” [Invited]
Masatoshi Kudo
Interntional Liver Cancer Association (ILCA) Annual Conference   15 Sep 2018   
Efficacy and safety of Tislelizumab, an anti-PD-1 antibody, versus sorafenib as a potential first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, multicenter study: A Trial-in-Progress
Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li C, Song J, Zhu AX
12th Annual Conference International Liver Cancer Association (ILCA)   15 Sep 2018   
Practice patterns in the treatment of unresectablehepatocellular carcinoma with sorafenibin Latin America according to Child–Pugh score: Subgroup analysis of the GIDEON study
Ladron de Guevara L, Dagher L, Miguel Viana Arruda V, Nakajima K, Kudo M
ALEH 2018   Sep 2018   
A prospective, observational study to assess the safety and effectiveness of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice (REFINE)
Finn R, Frenette C, Granito A, Ikeda M, Lim HY, Merle P, Ozgurdal K, Kudo M
12th Annual Conference International Liver Cancer Association (ILCA)   Sep 2018   
Hand–foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenibfor treatment of hepatocellular carcinoma (HCC) progressing on sorafenib
Silva M, Carrilho FJ, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Xu L, Baumhauer A, Meinhardt G, Han G, Bruix J, on behalf of the RESORCE Investigators
ALEH 2018   Sep 2018   
Invited Lecture “Eastern perspective” [Invited]
Masatoshi Kudo
Hepatocellular Carcinoma (HCC) Scientific Input Engagement   9 Aug 2018   
Educational Lecture “Phase 3 study of ramucirumab versus placebo in 2nd-line advanced HCC patients with high baseline AFP (REACH-2)”
Masatoshi Kudo
16th Annual Meeting of the Japanese Society of Medical Oncology   19 Jul 2018   
Chair: Oral Poster Presentation “Treatment: clinical trials” [Invited]
Masatoshi Kudo
The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   7 Jul 2018   
Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE): final analysis of OPTIMIS in Asian regions
Masatoshi Kudo
The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   7 Jul 2018   
Invited Lecture “TKI-Based combination therapy: the more the better?” [Invited]
Masatoshi Kudo
The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   7 Jul 2018   
Invited Lecture “TACE refractoriness: definition and treatment options” [Invited]
Masatoshi Kudo
The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   7 Jul 2018   
Invited Lecture “Role of contrast-enhanced ultrasound in diagnosis of early-stage HCC” [Invited]
Masatoshi Kudo
The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   6 Jul 2018   
Chair: Session 1 “Update of HCC guidelines” [Invited]
Masatoshi Kudo
The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   6 Jul 2018   
Safety and Effectiveness of Regorafenib in Patients with Unresectable Hepatocellular Carcinoma in Routine Clinical Practice: REFINE, a Prospective, Observational Study
Lim HY, Finn RS, Frenette C, Granito A, Ikeda M, Merle P, Ozgurdal K, Kudo M
The 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)   Jul 2018   
Invited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma” [Invited]
Masatoshi Kudo
Next Symposium   10 Jun 2018   
Similar efficacy and safety of endoscopic ultrasound-guided biliary drainage via hepaticogastrostomy and choledochoduodenostomy approaches for malignant distal obstruction: a multicenter, prospective randomized trial. Topic Forum “Exploring Newer Indicati
Minaga K, Kitano M, Ogura, T, Shiomi H, Hoki N, Nishikiori H, Yamashita Y, Hisa Takeshi, Kato H, Kamada H, Takenaka, M, Higuchi, K, Chiba Y, Kudo M
Digestive Disease Week (DDW 2018)   5 Jun 2018   
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafe
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Lim HY, Pracht M, Rau KM, Merle P, Motomura K, Ohno I, Daniele B, Shin D, Gerken G, Abada P, Hsu Y, Kudo M
American Society of Clinical Oncology Annual Meeting (ASCO 2018)   4 Jun 2018   
A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Mercade TM, Tomasello G, Boisserie F, Hou J, Li C, Song J, Zhu AX
American Society of Clinical Oncology Annual Meeting (ASCO 2018)   4 Jun 2018   
Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Kudo M, Ueshima K, Torimura T, Tanabe N, Ikeda M, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Isoda N, Yasui K, Kuzuya T, Okusaka T, Furuse J, Kokudo N, Okita K, Yoshimura K, Arai Y, TACTICS Trial Group
American Society of Clinical Oncology Annual Meeting (ASCO 2018)   3 Jun 2018   
Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis
Peck-Radosavljevic M, Kudo M, Raoul JL, Lee HC, Decaens T, Heo J, Lin SM, Shan H, Yang Y, Bayh I, Nakajima K, Cheng AL
American Society of Clinical Oncology Annual Meeting (ASCO 2018)   3 Jun 2018   
A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)
Ikeda M, Sung MW, Kudo M, Kobayashi M, Baron AD, Finn RS, Kaneko S, Zhu AX, Kubota T, Kraljevic S, Ishikawa K, Siegel AB, Kumada H, Okusaka T
American Society of Clinical Oncology Annual Meeting (ASCO 2018)   3 Jun 2018   
“Small HCCs”, Hot Issues: ACUCI “CEUS: how to maker it clear” [Invited]
Masatoshi Kudo
The 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018)   25 May 2018   
Expansion of color fusion outside the liver
Ogawa C, Morita M, Shibatoge M, Kudo M
The 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018)   24 May 2018   
Chair; Consensus Meeting “Guidelines for contrast-enhanced harmonic endoscopic ultrasonography” [Invited]
Masatoshi Kudo
The 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018)   23 May 2018   
Hand-foot syndrome as predictor of survival in advanced HCC treated with sorafenib
Ogawa C, Morita M, Shibatoge M, Takaguchi K, Tani J, Masaki T, Moriya A, Deguchi A, Kudo M
Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference   13 May 2018   
Keynote-224: Pembrolizumab in patients with advanced HCC previously treated with sorafenib
Kudo M, Zhu AX, Finn RS, Cattan S, Edeline J, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan S, Knox J, Daniele B
Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference   13 May 2018   
Invited Lecture “Molecular targeted therapy”, Symposium 6 “Aging society and HCC: up to what age do we consider treating patients with HCC in general?” [Invited]
Masatoshi Kudo
Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference   12 May 2018   
Studies on AFP, ALT abnormalities and hepatocarcinogenesis after SVR in chronic hepatitis C patients treated with direct acting antivirals
Kono M, Nishida N, Kudo M
Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference   11 May 2018   
Chair: Symposium 3 “HCC with vascular invasion: HAIC, radioembolization, radiation therapy, surgery, or systemic therapy?” [Invited]
Masatoshi Kudo
Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference   11 May 2018   
Invited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma” [Invited]
Masatoshi Kudo
Next Symposium   10 May 2018   
Keynote Lecture “The role of TKI in HCC in an immunotherapy world” [Invited]
Masatoshi Kudo
5th Asia-Pacific Gastroenterology Cancer Summit 2018   6 May 2018   
Invited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma” [Invited]
Masatoshi Kudo
Next Symposium   10 Apr 2018   
Invited Lecture “Novel management of advanced HCC” [Invited]
Masatoshi Kudo
5th Myanmar GI & Liver, International Scientific Meeting and ASEAN Perspective in Liver Diseases (APLD)   17 Feb 2018   
Invited Lecture “Systemic therapy for hepatocellular carcinoma: 2018 update” [Invited]
Masatoshi Kudo
The 33rd Nagoya International Cancer Treatment Symposium   10 Feb 2018   
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib
Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder VV, Gerolami R, Masi G, Ross PJ, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Xu L, Baumhauer A, Meinhardt G, Han G, on behalf of the RESORCE Investigators
Gastrointestinal Cancers Symposium (ASCO-GI 2018)   19 Jan 2018   
Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)
Lencioni R, Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Piscaglia F, Han G, Ikeda M, Simon K, Komov D, OuYang X, Evans TRJ, Sung MW, Binder TA, Damon A, Kraljevic S, Ren M, Ryoo BY
Gastrointestinal Cancers Symposium (ASCO-GI 2018)   19 Jan 2018